Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
RecruitingPhase 2/3
Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Must be able to understand and provide written informed consent 2. Age 18 or older 3. Clinical diagnosis of cutaneous warts 4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.) Exclusion Criteria: 1. Untreated cutaneous warts 2. Anogenital warts 3. Oral warts 4. Treatment for cutaneous warts in the past 4 weeks 5. Active acute illness 6. Immunosuppression 7. Known hypersensitivity to HPV vaccination 8. Subjects may not receive any other investigational treatment 9. Pregnancy or planned pregnancy during the study period
About the study
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
What is being tested
- Human Papillomavirus 9-valent Vaccine, Recombinant (biological)
- Normal Saline (other)
Sponsor: Western Institute for Veterans Research · Participants: 120 · Started: Mar 25, 2024
Contact the study team
- Lowell Nicholson, MD · Phone: 801-581-2121
- Jamie Rhoads, MD · Phone: 801-581-2121
Official record on ClinicalTrials.gov — NCT05625633
Locations in the U.S.
| Utah | University of Utah Midvalley Health Center, Salt Lake City VA Salt Lake City Health Care System, Salt Lake City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.